SCHEMBL18478692

SCHEMBL18478692

Cc1ncc(C)n2nc(C[C@H](C)c3nc4c5cccnc5ccc4n3C)nc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10309452 1.00 PDE10A (1.00) PDE10A
SCHEMBL10309345 0.87 PDE10A (0.78) PDE10A
SCHEMBL17254687 0.84 PDE10A (0.72) PDE10A
SCHEMBL19292041 0.84 PDE10A (0.72) PDE10A
SCHEMBL18478963 0.84 PDE10A (0.72) PDE10A
SCHEMBL10309346 0.82 PDE10A (0.70) PDE10A
SCHEMBL18634464 0.82 PDE10A (0.70) PDE10A
SCHEMBL10309432 0.82 PDE10A (0.74) PDE10A
SCHEMBL10309396 0.80 PDE10A (0.67) PDE10A
SCHEMBL18479356 0.76 PDE10A (0.76) PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9994590-B2 Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors SUNOVION PHARMACEUTICALS INC. (US) 2018-06-12 US disclosed
US-20170037060-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. 2017-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037060-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF COMT, GPR119, NLN PDE10A 2086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.